摘要
目的 探讨血清富亮氨酸α-2糖蛋白-1(LRG1)联合经典Wnt信号通路关键调控蛋白β-连环蛋白(β-catenin)在弥漫性大B细胞淋巴瘤(DLBCL)诊断与预后评估中的应用价值。方法 选取2017年10月至2019年10月济宁医学院附属金乡医院收治的86例DLBCL患者作为研究组,选择同期于本院接受治疗的淋巴结反应增生(RLNH)患者80例作为对照组;所有DLBCL患者给予R-CHOP方案化疗并评估化疗效果,分为缓解组和未缓解组;比较各组血清LRG1、β-catenin水平,分析血清LRG1、β-catenin水平与DLBCL患者临床病理特征的关系;分析血清LRG1、β-catenin在DLBCL患者诊断与预后评估的应用价值。结果 研究组血清LRG1、β-catenin水平显著高于对照组,差异有统计学意义(P<0.05)。DLBCL不同临床分期、淋巴细胞计数、美国东部协作肿瘤组体质状态(ECOG PS)评分及有无骨髓侵犯、结节受累患者血清LRG1、β-catenin水平比较差异有统计学意义(P<0.05)。DLBCL患者经R-CHOP方案化疗后缓解组患者血清LRG1、β-catenin水平显著低于未缓解组(P<0.05)。ROC曲线结果显示,LRG1、β-catenin及两者联合诊断DLBCL的曲线下面积(AUC)分别为0.791、0.756及0.807,联合检测的AUC显著高于单一检测(P<0.05)。COX多因素回归分析结果显示,血清LRG1、β-catenin与临床分期、骨髓侵犯、结节受累均为DLBCL患者预后的独立危险因素(P<0.05)。结论 血清LRG1、β-catenin在DLBCL患者中明显升高,二者均是影响DLBCL患者预后的独立危险因素,联合检测其水平对于DLBCL的诊断、治疗及预后具有显著价值。
Objective To explore the role of serum leucine-richα-2 glycoprotein-1(LRG1)combined with the key regulator proteinβ-catenin(β-catenin)of the canonical Wnt signaling pathway in the diagnosis and clinical significance of diffuse large B-cell lymphoma(DLBCL).Methods A total of 86 patients with DLBCL treated in Jinxiang Hospital Affiliated to Jining Medical College from October 2017 to October 2019 were selected as the research group,and 80 patients with reactive lymph node hyperplasia(RLNH)treated in our hospital during the same period were selected as the control group.All DLBCL patients were given R-CHOP chemotherapy,and the effect of chemotherapy was evaluated,and they were divided into the remission group and the non-remission group.The serum LRG1 andβ-catenin levels were compared among the groups,and the relationship between the serum LRG1 andβ-catenin levels and the clinicopathological features of DLBCL patients was analyzed.The application of serum LRG1 andβ-catenin in the diagnosis and prognosis assessment of DLBCL patients was analyzed.Results The serum LRG1 andβ-catenin levels in the study group were significantly higher than those in the control group(P<0.05).Statistically significant differences were found in the comparison of different clinical stages of DLBCL,lymphocyte counts,Eastern Cooperative Oncology Group Physical Status(ECOG PS)scores and serum LRG1 andβ-catenin levels in patients with or without bone marrow invasion and nodal involvement(P<0.05).After 86 patients were treated with R-CHOP chemotherapy,65 cases remitted,the remission rate was 75.6%,and the serum LRG1 andβ-catenin levels of patients in the remission group were significantly lower than those in the non-remission group(P<0.05).The ROC curve results showed that the area under the curve(AUC)of LRG1,β-catenin and combined in the diagnosis of DLBCL were 0.791,0.756 and 0.807,respectively.The results of COX multivariate regression analysis on the prognosis and survival factors of DLBCL patients showed that serum LRG1,β-catenin,clinical stage,bone marrow invasion,and nodular involvement were all independent risk factors for the prognosis of DLBCL patients(P<0.05).Conclusion Serum LRG1 andβ-catenin are significantly elevated in DLBC,both of which are independent risk factors affecting the prognosis of DLBCL patients.
作者
孙雷
范艳玲
张诒田
孙宗文
SUN Lei;FAN Yaning;ZHANG Yitian;SUN Zongwen(Department of Hematology and Oncology,Jinxiang Hospital Affiliated to Jining Medical College(Jinxiang County People's Hospital),Jining,Shandong,China,272200)
出处
《分子诊断与治疗杂志》
2023年第10期1689-1693,共5页
Journal of Molecular Diagnostics and Therapy
基金
山东省医药卫生科技发展计划项目(2017WS203)。
